Advertisement
Advertisement

Health Care Provider Survey: Looking for HIV+ Patients With No Remaining HIV Treatment Options

Search Currently Limited to Patients in the NY-CT-MA-NJ-PA Areas of the U.S.

September 16, 2011

Dear Colleague:

Over the past year, ACRIA has been working with key pharmaceutical companies, colleagues in San Francisco (Drs. Lalezari and Deeks), and a community HIV activist (Nelson Vergel) to develop a unique, multi-drug expanded access program (or 'salvage' protocol) for persons with HIV who are resistant to all currently-approved classes of antiretrovirals(ARVs).

Advertisement

With the support of the FDA, this protocol will permit the use of two or more experimental agents currently in late phase II or III clinical trials, but not yet FDA-approved, together with approved ARVs in a treatment regimen. We hope to begin enrolling patients in New York and San Francisco by early 2012.

Before we begin, it would be helpful to know how many patients might be eligible for such a protocol. Therefore, we would greatly appreciate your participation in a very short survey (4 questions 90 seconds!) at: https://www.surveymonkey.com/s/MDEAPNYC

Thank you for your assistance. We will be in touch very soon regarding our progress on this salvage protocol.

Sincerely,
Jerry Ernst, MD
Medical Director, Amida Care and ACRIA
&
Daniel Tietz
Executive Director, ACRIA




This article was provided by AIDS Community Research Initiative of America. Visit ACRIA's website to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.